Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)
Historic Other Non Operating Income for Avalo Therapeutics (AVTX) over the last 6 years, with Q3 2025 value amounting to -$3000.0.
- Avalo Therapeutics' Other Non Operating Income rose 4000.0% to -$3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13000.0, marking a year-over-year increase of 7234.04%. This contributed to the annual value of -$5000.0 for FY2024, which is 8809.52% up from last year.
- Latest data reveals that Avalo Therapeutics reported Other Non Operating Income of -$3000.0 as of Q3 2025, which was up 4000.0% from -$5000.0 recorded in Q2 2025.
- Avalo Therapeutics' 5-year Other Non Operating Income high stood at $100000.0 for Q3 2023, and its period low was -$180000.0 during Q1 2023.
- Over the past 5 years, Avalo Therapeutics' median Other Non Operating Income value was -$5000.0 (recorded in 2021), while the average stood at -$19545.5.
- As far as peak fluctuations go, Avalo Therapeutics' Other Non Operating Income tumbled by 80000.0% in 2023, and later skyrocketed by 4000.0% in 2025.
- Over the past 5 years, Avalo Therapeutics' Other Non Operating Income (Quarter) stood at -$15000.0 in 2021, then crashed by 33.33% to -$20000.0 in 2022, then soared by 490.0% to $78000.0 in 2023, then tumbled by 106.41% to -$5000.0 in 2024, then surged by 40.0% to -$3000.0 in 2025.
- Its Other Non Operating Income was -$3000.0 in Q3 2025, compared to -$5000.0 in Q2 2025 and -$5000.0 in Q3 2024.